JPWO2021251467A1 - - Google Patents

Info

Publication number
JPWO2021251467A1
JPWO2021251467A1 JP2022530623A JP2022530623A JPWO2021251467A1 JP WO2021251467 A1 JPWO2021251467 A1 JP WO2021251467A1 JP 2022530623 A JP2022530623 A JP 2022530623A JP 2022530623 A JP2022530623 A JP 2022530623A JP WO2021251467 A1 JPWO2021251467 A1 JP WO2021251467A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530623A
Other languages
Japanese (ja)
Other versions
JPWO2021251467A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021251467A1 publication Critical patent/JPWO2021251467A1/ja
Publication of JPWO2021251467A5 publication Critical patent/JPWO2021251467A5/ja
Priority to JP2025016373A priority Critical patent/JP2025069332A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022530623A 2020-06-10 2021-06-10 Pending JPWO2021251467A1 (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025016373A JP2025069332A (ja) 2020-06-10 2025-02-03 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020101161 2020-06-10
PCT/JP2021/015338 WO2021250995A1 (ja) 2020-06-10 2021-04-13 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態
PCT/JP2021/022157 WO2021251467A1 (ja) 2020-06-10 2021-06-10 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025016373A Division JP2025069332A (ja) 2020-06-10 2025-02-03 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Publications (2)

Publication Number Publication Date
JPWO2021251467A1 true JPWO2021251467A1 (https=) 2021-12-16
JPWO2021251467A5 JPWO2021251467A5 (https=) 2023-08-23

Family

ID=78845537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530623A Pending JPWO2021251467A1 (https=) 2020-06-10 2021-06-10
JP2025016373A Pending JP2025069332A (ja) 2020-06-10 2025-02-03 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025016373A Pending JP2025069332A (ja) 2020-06-10 2025-02-03 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Country Status (3)

Country Link
JP (2) JPWO2021251467A1 (https=)
CN (1) CN115916781A (https=)
WO (2) WO2021250995A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250995A1 (ja) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123282A1 (en) * 2011-11-16 2013-05-16 Leonid Metsger Solid state forms of linagliptin
WO2013128379A2 (en) * 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Crystalline polymorphic forms of linagliptin
JP2016222734A (ja) * 2006-05-04 2016-12-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
KR20170078036A (ko) * 2015-12-29 2017-07-07 (주) 에프엔지리서치 무정형 리나글립틴의 제조 방법
CN107043376A (zh) * 2017-05-15 2017-08-15 珠海联邦制药股份有限公司 一种利格列汀新晶型及其制备方法
CN108017638A (zh) * 2016-10-31 2018-05-11 江苏艾立康药业股份有限公司 一种利格列汀晶型的制备方法
JP2018177769A (ja) * 2017-04-07 2018-11-15 イルドン ファーマシューティカル カンパニー リミテッド １−［（４−メチル−キナゾリン−２−イル）メチル］−３−メチル−７−（２−ブチン−１−イル）−８−（３−（ｒ）−アミノ−ピペリジン−１−イル）−キサンチンの新規結晶形及びその製造方法
CN110305131A (zh) * 2019-07-03 2019-10-08 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN103319483B (zh) * 2012-10-19 2016-08-03 药源药物化学（上海）有限公司 一种利拉列汀重要中间体的制备方法
KR102442536B1 (ko) * 2015-09-17 2022-09-13 한미정밀화학주식회사 리나글립틴 결정형 및 이의 제조방법
CN106554354B (zh) * 2015-09-28 2019-03-19 四川科伦药物研究院有限公司 利格列汀或其类似物的中间体与利格列汀或其类似物的制备方法
CN105272982B (zh) * 2015-11-23 2017-06-16 齐鲁制药有限公司 利格列汀新晶型及其制备方法
CN110964013B (zh) * 2018-09-29 2023-04-07 甘李药业股份有限公司 利格列汀及其中间体的制备方法
JP6947354B2 (ja) * 2018-10-31 2021-10-13 ヤマサ醤油株式会社 リナグリプチンの製造法
CN109761983B (zh) * 2019-02-11 2022-03-04 深圳市第二人民医院 一种利格列汀的制备方法
WO2021250995A1 (ja) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 １－［（４－メチル－キナゾリン－２－イル）メチル］－３－メチル－７－（２－ブチン－１－イル）－８－（３－（ｒ）－アミノ－ピペリジン－１－イル）－キサンチンの結晶形態

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016222734A (ja) * 2006-05-04 2016-12-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
US20130123282A1 (en) * 2011-11-16 2013-05-16 Leonid Metsger Solid state forms of linagliptin
WO2013074817A1 (en) * 2011-11-16 2013-05-23 Assia Chemical Industries Ltd. Solid state forms of linagliptin
WO2013128379A2 (en) * 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Crystalline polymorphic forms of linagliptin
KR20170078036A (ko) * 2015-12-29 2017-07-07 (주) 에프엔지리서치 무정형 리나글립틴의 제조 방법
CN108017638A (zh) * 2016-10-31 2018-05-11 江苏艾立康药业股份有限公司 一种利格列汀晶型的制备方法
JP2018177769A (ja) * 2017-04-07 2018-11-15 イルドン ファーマシューティカル カンパニー リミテッド １−［（４−メチル−キナゾリン−２−イル）メチル］−３−メチル−７−（２−ブチン−１−イル）−８−（３−（ｒ）−アミノ−ピペリジン−１−イル）−キサンチンの新規結晶形及びその製造方法
CN107043376A (zh) * 2017-05-15 2017-08-15 珠海联邦制药股份有限公司 一种利格列汀新晶型及其制备方法
CN110305131A (zh) * 2019-07-03 2019-10-08 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005707246 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005707247 *

Also Published As

Publication number Publication date
WO2021250995A1 (ja) 2021-12-16
WO2021251467A1 (ja) 2021-12-16
CN115916781A (zh) 2023-04-04
JP2025069332A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
JPWO2021251467A1 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20251201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202